@article {Hanawa891, author = {Shinsuke Hanawa and Akira Mitsuhashi and Hirokazu Usui and Noriko Yamamoto and Miho Watanabe-Nemoto and Kyoko Nishikimi and Takashi Uehara and Shinichi Tate and Takashi Uno and Makio Shozu}, title = {Daily Low-Dose Cisplatin-Based Concurrent Chemoradiotherapy for the Treatment of Cervical Cancer in Patients 70 Years or Older}, volume = {25}, number = {5}, pages = {891--896}, year = {2015}, doi = {10.1097/IGC.0000000000000436}, publisher = {BMJ Specialist Journals}, abstract = {Objectives It has been established that concurrent chemoradiotherapy (CCRT) is efficacious for cervical cancer, but adherence is unsatisfactory among elderly patients. To improve adherence, we have developed and initiated a daily low-dose cisplatin-based CCRT regimen. Here, we retrospectively evaluated the use of CCRT, especially for elderly patients.Methods The study included a total of 53 patients who were 70 years or older, had stage IB-IVA cervical cancer, and were initially treated with daily CCRT. The daily CCRT comprised pelvic external beam radiotherapy (2 Gy/d {\texttimes} 25) with daily low-dose cisplatin (8.0 mg/m2 per day) and either low- or high-dose-rate intracavitary brachytherapy.Results The median age was 72 years (range, 70{\textendash}85 years). The median follow-up duration was 32 months (range, 2{\textendash}104 months). The 3-year overall survival rate was 79.0\%. Daily cisplatin chemotherapy was successfully completed in 32 (60.4\%) of the 53 patients. Grade 3 or 4 neutropenia was observed in 19 patients (36\%). A late complication of grade 3 rectal hemorrhage occurred in 3 patients who received high-dose-rate brachytherapy. All primary tumors responded to daily CCRT; complete response was observed in 43 patients (91.5\%) and partial response was observed in 4 patients (8.5\%).Conclusions Daily CCRT in patients 70 years and older had acceptable compliance and safety. Daily CCRT is suggested to be a good treatment option for elderly patients who have advanced cervical cancer and require concurrent cisplatin.}, issn = {1048-891X}, URL = {https://ijgc.bmj.com/content/25/5/891}, eprint = {https://ijgc.bmj.com/content/25/5/891.full.pdf}, journal = {International Journal of Gynecologic Cancer} }